BioSpace News Archive

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced the appointments of Samik Basu, M.D. to Chief Scientific Officer (CSO) and Heather Harte-Hall to Chief Compliance Officer (CCO).

Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the presentation of preclinical data highlighting the potential of neoantigen-specific TCR-T cells for the treatment of solid tumors at the Society for Immunotherapy of Cancer 2021 Annual Meeting.

Shape Therapeutics Inc. (ShapeTX), today announced the appointment of David J. Huss, Ph.D., as Chief Scientific Officer (CSO) and Lisa Taylor Ash, J.D., as General Counsel of ShapeTX.

Agenus Corporate Update and Third Quarter 2021 Financial Report

Lexicon Pharmaceuticals, Inc. today announced that a new analysis of sotagliflozin results from the SOLOIST and SCORED Phase 3 outcomes studies will be presented at the virtual American Heart Association Scientific Sessions 2021.

Selecta Biosciences Reports Third Quarter 2021 Financial Results and Provides Business Update

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces final OS data from its Phase IIb AIPAC trial which are being presented in a late breaker presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021 held from 10-14 November 2021.

Ascendis Pharma A/S (Nasdaq: ASND) today announced two poster presentations featuring new non-clinical data for its investigational TransCon™ TLR7/8 Agonist product candidate at SITC 2021, the annual meeting for the Society for Immunotherapy of Cancer taking place virtually and in person November 10-14 in Washington, D.C.

Aadi Bioscience, Inc. today announced that management will be participating in the upcoming Jefferies London Healthcare Conference and the Piper Sandler Virtual Healthcare Conference.

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported its financial results for the three and nine months ended September 30, 2021 and provided a business update.